Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nanjing Medlander Medical Technology Co (688273) Fair Value & Analysis

Healthcare · CN · Market cap 4.0B CNY

Price¥42.30
Fair Value¥18.78
Upside-55.6%
Quality93/100
Evidence: High Range ¥13.15 – ¥25.89

Analysis

Nanjing Medlander Medical Technology Co (688273) currently trades at ¥42.30, while our model-based Fair Value estimate is ¥18.78 — implying the stock looks roughly 55.6% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes. The company also provides electronic colposcopes, biofeedback stimulation devices, high-frequency electrocautery devices, ultrasonic uterine involution devices, and electro-ultrasound therapy devices; and finger joint rehabilitation assessment systems, portable hand function rehabilitation assessment systems, hand function magnetic stimulation systems, transcranial magnetic stimulation systems, biofeedback devices, and portable biofeedback devices. In addition, it provides pelvic floor muscle rehabilitation devices an…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -23% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.